Literature DB >> 33268234

Impact of systemic corticosteroids on survival outcomes in immune checkpoint inhibitor-induced gastroenterocolitis.

Leah L Thompson1, Ethan Katznelson1, Donna E Leet1, Sienna M Durbin1, Jaewon Yoon1, Kerry L Reynolds1, Michael L Dougan2, Steven T Chen3.   

Abstract

Mesh：

Substances：

Year:  2020        PMID： 33268234      PMCID： PMC8300871          DOI： 10.1016/j.ejca.2020.09.022

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  7 in total

Review 1.  Immune regulation by glucocorticoids.

Authors:  Derek W Cain; John A Cidlowski
Journal:  Nat Rev Immunol       Date:  2017-02-13       Impact factor: 53.106

2.  Management of Patients With Immune Checkpoint Inhibitor-Induced Enterocolitis: A Systematic Review.

Authors:  Michael Collins; Emilie Soularue; Lysiane Marthey; Franck Carbonnel
Journal:  Clin Gastroenterol Hepatol       Date:  2020-01-31       Impact factor: 11.382

3.  High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma.

Authors:  Alexander T Faje; Donald Lawrence; Keith Flaherty; Christine Freedman; Riley Fadden; Krista Rubin; Justine Cohen; Ryan J Sullivan
Journal:  Cancer       Date:  2018-07-05       Impact factor: 6.860

4.  Management of Immunotherapy-Related Toxicities, Version 1.2019.

Authors:  John A Thompson; Bryan J Schneider; Julie Brahmer; Stephanie Andrews; Philippe Armand; Shailender Bhatia; Lihua E Budde; Luciano Costa; Marianne Davies; David Dunnington; Marc S Ernstoff; Matthew Frigault; Brianna Hoffner; Christopher J Hoimes; Mario Lacouture; Frederick Locke; Matthew Lunning; Nisha A Mohindra; Jarushka Naidoo; Anthony J Olszanski; Olalekan Oluwole; Sandip P Patel; Sunil Reddy; Mabel Ryder; Bianca Santomasso; Scott Shofer; Jeffrey A Sosman; Momen Wahidi; Yinghong Wang; Alyse Johnson-Chilla; Jillian L Scavone
Journal:  J Natl Compr Canc Netw       Date:  2019-03-01       Impact factor: 11.908

5.  Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center.

Authors:  Troy Z Horvat; Nelly G Adel; Thu-Oanh Dang; Parisa Momtaz; Michael A Postow; Margaret K Callahan; Richard D Carvajal; Mark A Dickson; Sandra P D'Angelo; Kaitlin M Woo; Katherine S Panageas; Jedd D Wolchok; Paul B Chapman
Journal:  J Clin Oncol       Date:  2015-08-17       Impact factor: 44.544

Review 6.  Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors.

Authors:  Satya Das; Douglas B Johnson
Journal:  J Immunother Cancer       Date:  2019-11-15       Impact factor: 13.751

Review 7.  Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson.

Authors:  Yinghong Wang; Hamzah Abu-Sbeih; Emily Mao; Noman Ali; Faisal Shaukat Ali; Wei Qiao; Phillip Lum; Gottumukkala Raju; Gladis Shuttlesworth; John Stroehlein; Adi Diab
Journal:  J Immunother Cancer       Date:  2018-05-11       Impact factor: 13.751
  7 in total
  2 in total

Review 1.  Mechanism and Management of Checkpoint Inhibitor-Related Toxicities in Genitourinary Cancers.

Authors:  Haoran Li; Kamal K Sahu; Benjamin L Maughan
Journal:  Cancers (Basel)       Date:  2022-05-17       Impact factor: 6.575

Review 2.  Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management.

Authors:  Liansha Tang; Jialing Wang; Nan Lin; Yuwen Zhou; Wenbo He; Jiyan Liu; Xuelei Ma
Journal:  Front Immunol       Date:  2021-12-21       Impact factor: 7.561
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.